177Lu-BETABART

177Lu-BETABART is a radiopharmaceutical therapeutic agent composed of a humanized monoclonal IgG1 antibody specifically engineered to bind with high affinity to the 4Ig isoform of **B7-H3 (CD276)**, an immune checkpoint protein highly expressed in multiple solid tumor types and minimally in normal tissues[1][3][7][10]. The antibody is conjugated to the radioactive isotope **Lutetium-177**, enabling the local delivery of ionizing radiation directly to B7-H3-expressing tumor cells[1][7][10]. The drug is designed to maximize tumor targeting while minimizing systemic toxicity through hepatic clearance and optimized pharmacokinetics. Preclinical data demonstrate anti-tumor effects including tumor shrinkage and survival benefit[1][7][10]. Developed as a first-in-class targeted radiopharmaceutical, it is anticipated for clinical use in patients with aggressive, refractory solid tumors[1][3][4][7][10].

Brand names

177Lu-BETABARTBetabart

Other names

B7-H3(Radiopharm Ventures)Radiolabelled humanized IgG antibodyRadiolabelled humanized immunoglobulin G antibody